Search results
Results from the Go Local Guru Content Network
The Flint MTA received a $7.985 million grant from the Federal Transit Administration that was funded by the American Recovery and Reinvestment Act of 2009 for new Project 25 digital radio dispatch equipment and mobile data terminals, new intelligent transportation system software and equipment, preventive maintenance, and the purchase and ...
Politics & Government The MTA Will Pay $1M For Your 'Genius' Idea On How To Fix The NYC Subway (New Details!) The three winners of the "MTA Genius Transit Challenge" will be awarded $1 million each.
MTA board members voted 11-1 Wednesday to approve a congestion pricing structure that includes a $15 toll for most vehicles to enter Manhattan at 60th Street and below.
The Cray MTA, formerly known as the Tera MTA, is a supercomputer architecture based on thousands of independent threads, fine-grain communication and synchronization between threads, and latency tolerance for irregular computations. Each MTA processor ( CPU) has a high-performance ALU with many independent register sets, each running an ...
The MTA plans to bring OMNY to all 472 subway stations and all bus routes by the end of next year, and the agency will introduce its own contactless transit card in 2021.
The fleet consists of over 5,700 buses of various types and models for fixed-route service, making MTA RBO's fleet the largest public bus fleet in the United States. The MTA also has over 2,000 vans and cabs for ADA paratransit service, providing service in New York City, southwestern Nassau County, and the city of Yonkers.
John Nathan Lieber. ( 1961-09-19) September 19, 1961 (age 62) Education. Harvard University ( BA) New York University ( JD) John Nathan " Janno " Lieber (born September 19, 1961) [1] is the head of the Metropolitan Transportation Authority (MTA) in New York. He was appointed acting chair and CEO in July 2021 and confirmed permanently in January ...
4-Methylthioamphetamine ( 4-MTA) is a designer drug of the substituted amphetamine class developed in the 1990s by a team led by David E. Nichols, an American pharmacologist and medical chemist, at Purdue University. It acts as a non- neurotoxic highly selective serotonin releasing agent (SSRA) in animals.